Affiliation: Uppsala University Hospital
Lindholm D, Storey R, Christersson C, Halvorsen S, Grove E, Braun O, et al
. Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. Am Heart J. 2015;170:465-70 pubmed publisher
..This trial will determine if adenosine antagonism by caffeine can alleviate ticagrelor-related dyspnea, without impairing the antiplatelet effect of ticagrelor. ..
Lindholm D, James S. Bioresorbable Stents in PCI. Curr Cardiol Rep. 2016;18:74 pubmed publisher
..Further development and longer-term studies are needed before the routine implementation of bioresorbable stents in clinical practice. ..
Lindholm D, James S, Bertilsson M, Becker R, Cannon C, Giannitsis E, et al
. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem. 2017;63:573-584 pubmed publisher
..This information may be useful for selection of patients who might benefit from more intense and/or prolonged antithrombotic treatment. ClinicalTrials.gov Identifier: NCT00391872. ..
Lindholm D, Lindback J, Armstrong P, Budaj A, Cannon C, Granger C, et al
. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. J Am Coll Cardiol. 2017;70:813-826 pubmed publisher
..The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial [STABILITY]; NCT00799903). ..
Lindholm D, Hagström E, James S, Becker R, Cannon C, Himmelmann A, et al
. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. J Am Heart Assoc. 2017;6: pubmed publisher
..GDF-15 levels may therefore be useful as part of decision support concerning long-term antithrombotic treatment in patients post-ACS. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00391872. ..